Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin

---
identifier: "/us/fr/E9-26787"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin"
title_number: 0
title_name: "Federal Register"
section_number: "E9-26787"
section_name: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin"
positive_law: false
currency: "2009-11-06"
last_updated: "2009-11-06"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "E9-26787"
document_type: "notice"
publication_date: "2009-11-06"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "74 FR 57460"
fr_volume: 74
fr_action: "Notice."
---


#  Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin

**AGENCY:**

Department of the Army, DoD.

**ACTION:**

Notice.

**SUMMARY:**

Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/252,675 entitled “Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin,” filed October 18, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

**ADDRESSES:**

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

The invention relates to the use of enhanced substrates for the protease activity of serotype A botulinum neurotoxin.

Brenda S. Bowen,

Army Federal Register Liaison Officer.